secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066933
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana reports Q1 net loss $49.4M, cash runway into 2026; new $119M ATM facility
------------------------------------------------------------------------------

- Net loss $49.4M ($0.21/share) vs $107.5M ($0.49/share) in Q1 2024; loss narrowed.
- Cash $104.7M at Mar 31, 2025, down from $152.5M; non-GAAP cash burn $46.6M; runway into 2026.
- Positive 12-week data for UP421 (HIP islet cells) in T1D: C-peptide production, immune evasion without immunosuppression.
- Enrolling GLEAM (autoimmune) and VIVID (B-cell malignancies) trials; expect data in 2025.
- New at-the-market (ATM) agreement with TD Cowen to sell up to $119M of common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/0000950170-25-066933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017025066933/sana-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer